Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Short Interest Up 57.3% in December

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMDGet Rating) was the target of a large growth in short interest in December. As of December 30th, there was short interest totalling 146,900 shares, a growth of 57.3% from the December 15th total of 93,400 shares. Based on an average daily volume of 116,100 shares, the days-to-cover ratio is currently 1.3 days. Approximately 0.7% of the shares of the company are sold short.

Analyst Ratings Changes

Separately, StockNews.com started coverage on shares of Galmed Pharmaceuticals in a research note on Monday, January 16th. They issued a “sell” rating for the company. One equities research analyst has rated the stock with a sell rating and five have given a hold rating to the company’s stock. According to data from MarketBeat.com, Galmed Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $5.00.

Galmed Pharmaceuticals Trading Up 7.3 %

Shares of Galmed Pharmaceuticals stock opened at $0.75 on Friday. The firm has a market capitalization of $18.85 million, a PE ratio of -0.83 and a beta of 1.10. The company has a current ratio of 4.07, a quick ratio of 4.07 and a debt-to-equity ratio of 0.01. The firm’s 50 day moving average is $0.48 and its 200 day moving average is $0.45. Galmed Pharmaceuticals has a 1 year low of $0.29 and a 1 year high of $1.84.

Galmed Pharmaceuticals (NASDAQ:GLMDGet Rating) last posted its earnings results on Wednesday, November 16th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.06). Equities research analysts forecast that Galmed Pharmaceuticals will post -0.73 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Western Wealth Management LLC acquired a new position in shares of Galmed Pharmaceuticals during the 2nd quarter valued at $38,000. Raymond James Financial Services Advisors Inc. increased its stake in Galmed Pharmaceuticals by 158.9% during the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 63,310 shares of the biopharmaceutical company’s stock valued at $101,000 after purchasing an additional 38,856 shares in the last quarter. Cambridge Investment Research Advisors Inc. bought a new stake in Galmed Pharmaceuticals during the 1st quarter valued at $42,000. Finally, Millennium Management LLC grew its stake in shares of Galmed Pharmaceuticals by 372.3% in the 2nd quarter. Millennium Management LLC now owns 50,748 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 40,003 shares in the last quarter. Institutional investors and hedge funds own 10.30% of the company’s stock.

Galmed Pharmaceuticals Company Profile

(Get Rating)

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.

See Also

Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.